Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555451 | 1.00 | CYP2C19 (0.56) | CYP2C19ALDH1A1CYP1A2USP2LMNA | |
| SCHEMBL27683934 | 1.00 | CYP2C19 (0.56) | CYP2C19ALDH1A1CYP1A2USP2LMNA | |
| SCHEMBL2941358 | 0.97 | CYP2C19 (0.52) | CYP2C19ALDH1A1CYP1A2USP2LMNA | |
| SCHEMBL322137 | 0.92 | — | — | |
| SCHEMBL3019549 | 0.86 | — | — | |
| SCHEMBL30962310 | 0.78 | CYP2C19 (0.37) | CYP2C19ALDH1A1CYP1A2USP2LMNA | |
| SCHEMBL28006632 | 0.78 | CYP2C19 (0.47) | CYP2C19ALDH1A1CYP1A2USP2LMNA | |
| SCHEMBL13545394 | 0.77 | CYP2C19 (0.47) | CYP2C19ALDH1A1CYP1A2USP2LMNA | |
| SCHEMBL4770611 | 0.77 | CYP2C19 (0.47) | CYP2C19ALDH1A1CYP1A2USP2LMNA | |
| SCHEMBL3345554 | 0.76 | CYP2C19 (0.58) | CYP2C19ALDH1A1CYP1A2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110029356-B | method for preparing ketone or β -carbonyl ester controlled by electrochemical oxidation method | 北京大学 | 2020-06-02 | — | — | CN | disclosed |
| EP-2124562-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-04-20 | — | — | EP | disclosed |
| CN-101686680-B | Bicyclic heteroaryl compounds as P2X7 modulators and uses thereof | Ivotec America Inc. (US) | 2015-12-09 | — | — | CN | disclosed |
| US-8093265-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-07-22 | — | — | US | disclosed |
| EP-2124562-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | disclosed |
| WO-2008112205-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007109201-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| CN-1897950-A | Fused aryl and heteroaryl derivatives and methods of use thereof | WYETH CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1898222-A | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH CORP (US) | 2007-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | CYP2C19 1237/4885ALDH1A1 3335/4885CYP1A2 1291/4885 |
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | CYP2C19 1078/4885ALDH1A1 3640/4885CYP1A2 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.